Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system

European Journal of Clinical Pharmacology

Volumn 51, Issue 3-4, 1996, Pages 327-330

  Muller P ^a,b   Botta, L ^b   Ezzet, F ^b  

^a CIBA GEIGY LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

bioequivalence; hormone replacement therapy; estradiol; pharmacokinetics; postmenopausal volunteers

Indexed keywords

ESTRADIOL; ESTRONE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTRONE; HUMANS; MIDDLE AGED;

EID: 0030471453     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050206     Document Type: Article

References (14)

1. Balfour JA, Heel RC (1990) Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 40:561-582
2. Balfour JA, McTavish D (1992) Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs and Aging 2:487-507
3. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA (1985) Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gyn 152:1099-1106
4. Nichols KC, Schenkel L, Benson H (1984) 17β-Estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv 39:230-245
5. Berner B, John VA (1994) Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 26:121-134
6. Ducros B, Bonnin JP, Navarranne A, Colomb D (1989) Eczéma de contact à l'éthanol contenu dans une pastille d'oestradiol transdermique (Estraderm TTS 50). Nouv Derm 8:21-22
7. Fisher AA (1988) Contact dermatitis: highlights from the 1987 Meeting of the American Academy of Dermatology, San Antonio, Texas. Cutis 41:87-88
8. Torres V, Lopes JC, Leite L (1992) Allergic contact dermatitis from nitroglycerin and estradiol transdermal therapeutic systems. Contact Derm 26:53-54
9. McBurney EI, Noel SB, Collins JH (1989) Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol 20:508-510
10. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL, Coombes RC (1987) Use of the aromatase inhibitor 4-hydroxy-androstenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 47:1957-1961
11. Trunet PF, Mueller Ph, Girard F, Aupetit B, Bhatnagar AS, Zognbi F, Ezzet F, Menard J (1992) The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab 74:571-576
12. Ritschel WA (1986) Handbook of basic pharmacokinetics, 3rd edn. Drug Intelligence Publications, Hamilton IL
13. Sauter R, Steinijans VW, Diletti E, Böhm A, Schulz H-H (1992) Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30:233-256
14. Cheang A, Sitruk-Ware R, Utian WH (1993) A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf 9:365-379